ArticleCancer immunology, immunotherapy : CII2018
Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab.
Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review.Advances in therapy · 2021Pooled it
- Cross-sectional mediation analysis of systemic inflammation in the association between serum uric acid and diabetic kidney disease: Evidence from NHANES 1999-2018.Metabolism open · 2025Article
- Prognostic factors in advanced incurable HNSCC patients on palliative-intent immunotherapy-based regimen.Future science OA · 2025Article
- The aggregate index of systemic inflammation is positively correlated with the risk of all-cause mortality in sepsis-associated acute kidney injury.Scientific reports · 2025Article
- Variation in CBC-Derived Inflammatory Biomarkers Across Histologic Subtypes of Lung Cancer: Can Histology Guide Clinical Management?Diagnostics (Basel, Switzerland) · 2025Article
- Differentiating Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Using Blood Composite Scores: Insights into Clinical Outcomes and Predictive Indices.Pediatric cardiology · 2025Article
- The Impact of the Histologic Types of Lung Cancer on CBC-Derived Inflammatory Markers-Current Knowledge and Future Perspectives.Journal of clinical medicine · 2025Article
- Efficient Predictor for Immunotherapy Efficacy: Detecting Pan-Clones Effector Tumor Antigen-Specific T Cells in Blood by Nanoparticles Loading Whole Tumor Antigens.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Association of aggregate index of systemic inflammation with increased all-cause and cardiovascular mortality in female cancer patients.Frontiers in oncology · 2025Article
- Association between the aggregate index of systemic inflammation and CKD: evidence from NHANES 1999-2018.Frontiers in medicine · 2025Article
- Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy.Current oncology (Toronto, Ont.) · 2024Article
- A predictive model to explore risk factors for severe COVID-19.Scientific reports · 2024Article
- NLR, MLR, and PLR are adverse prognostic variables for sleeve lobectomy within non-small cell lung cancer.Thoracic cancer · 2024Article
- The association between pan-immune-inflammation value and chronic obstructive pulmonary disease: data from NHANES 1999-2018.Frontiers in physiology · 2024Article
- The association between the aggregate index of systemic inflammation and risk of rheumatoid arthritis: retrospective analysis of NHANES 1999-2018.Frontiers in medicine · 2024Article
- The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma.Frontiers in oncology · 2024Article
- [Construction of a prognostic nomogram combining PET/CT metabolic parameters and blood inflammatory markers for non-small cell lung cancer treated with first-line chemotherapy].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond.Biomolecules · 2023Review
- Combined systemic inflammatory indexes as reflectors of outcome in patients with COVID‑19 infection admitted to ICU.Inflammopharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the most common malignancy worldwide. Despite significant advances in diagnosis and treatment, mortality rates remain extremely high, close to incidence rates. Several targeted therapies have been recently introduced for the treatment of non-small cell lung cancer (NSCLC), the most common type of lung cancer. Nivolumab, a monoclonal antibody that targets programmed death-1 (PD-1), was the first immune checkpoint inhibitor approved for the treatment of patients with advanced/metastatic NSCLC not responding to platinum-based chemotherapy. Biomarkers predicting response to these therapies would allow early identification of non-responders and timely implementation of appropriate combination strategies, avoiding inadequate and expensive therapies. The role of the neutrophil to lymphocyte ratio and other blood cell count indexes as possible biomarkers of response has been recently investigated. We discuss the encouraging results reported on the topic, provide new data from our personal experience, and discuss opportunities for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.